TARS – tarsus pharmaceuticals, inc. (US:NASDAQ)

News

Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
Tarsus Pharmaceuticals (TARS) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $98.00 price target on the stock.
Tarsus Pharmaceuticals (TARS) had its "sell (d-)" rating reaffirmed by Weiss Ratings.
Tarsus Pharmaceuticals (TARS) was downgraded by Wall Street Zen from
Tarsus Pharmaceuticals: Marketing Spend Bears Fruit, Pipeline Progresses [Seeking Alpha]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com